These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1184 related items for PubMed ID: 27387559

  • 1. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H, Ichiyanagi O, Naito S, Bilim VN, Tomita Y, Kato T, Nagaoka A, Tsuchiya N.
    BMC Cancer; 2016 Jul 07; 16():393. PubMed ID: 27387559
    [Abstract] [Full Text] [Related]

  • 2. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K, Miyake H, Kumano M, Fujisawa M.
    Br J Cancer; 2013 Oct 29; 109(9):2389-95. PubMed ID: 24091619
    [Abstract] [Full Text] [Related]

  • 3. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism.
    Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, Sun KH.
    Mol Cancer Res; 2012 Aug 29; 10(8):1109-19. PubMed ID: 22707636
    [Abstract] [Full Text] [Related]

  • 4. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
    Wang C, Cigliano A, Jiang L, Li X, Fan B, Pilo MG, Liu Y, Gui B, Sini M, Smith JW, Dombrowski F, Calvisi DF, Evert M, Chen X.
    Hepatology; 2015 Jan 29; 61(1):200-13. PubMed ID: 25145583
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q, Qin S, Zhang H, Liu B, Qin J, Wang X, Zhang R, Liu C, Dong X, Zhang S, Huang S, Chen L.
    J Cell Physiol; 2018 Jan 29; 233(1):516-529. PubMed ID: 28300280
    [Abstract] [Full Text] [Related]

  • 6. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 29; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 7. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
    Coffey RT, Shi Y, Long MJ, Marr MT, Hedstrom L.
    J Biol Chem; 2016 Mar 04; 291(10):5221-33. PubMed ID: 26740621
    [Abstract] [Full Text] [Related]

  • 8. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, Kim HL.
    PLoS One; 2013 Mar 04; 8(1):e54918. PubMed ID: 23349989
    [Abstract] [Full Text] [Related]

  • 9. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J.
    Cell Cycle; 2015 Mar 04; 14(2):232-42. PubMed ID: 25607647
    [Abstract] [Full Text] [Related]

  • 10. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
    Khor ES, Wong PF.
    Int J Biochem Cell Biol; 2018 Aug 04; 101():64-73. PubMed ID: 29857052
    [Abstract] [Full Text] [Related]

  • 11. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
    Li X, Hou G, Zhu Z, Yan F, Wang F, Wei D, Zheng Y, Yuan J, Zheng W, Zhang G, Meng P, Guo Y, Li X, Yao L, Shen L, Yuan J.
    Invest New Drugs; 2020 Aug 04; 38(4):956-966. PubMed ID: 31463638
    [Abstract] [Full Text] [Related]

  • 12. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
    Misra UK, Pizzo SV.
    J Cell Biochem; 2012 May 04; 113(5):1488-500. PubMed ID: 22173835
    [Abstract] [Full Text] [Related]

  • 13. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG.
    J Pathol; 2005 Mar 04; 205(4):498-506. PubMed ID: 15714459
    [Abstract] [Full Text] [Related]

  • 14. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
    Tomek K, Wagner R, Varga F, Singer CF, Karlic H, Grunt TW.
    Mol Cancer Res; 2011 Dec 04; 9(12):1767-79. PubMed ID: 21970855
    [Abstract] [Full Text] [Related]

  • 15. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W, Ye Q, Liu S, She QB.
    Oncotarget; 2015 Jun 10; 6(16):13962-77. PubMed ID: 25961827
    [Abstract] [Full Text] [Related]

  • 16. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.
    Int J Oncol; 2009 Oct 10; 35(4):731-40. PubMed ID: 19724909
    [Abstract] [Full Text] [Related]

  • 17. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.
    BMC Cancer; 2014 May 28; 14():376. PubMed ID: 24886512
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
    Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA.
    Cell Cycle; 2014 May 28; 13(5):820-33. PubMed ID: 24407515
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H.
    Leuk Res; 2007 May 28; 31(5):673-82. PubMed ID: 17007924
    [Abstract] [Full Text] [Related]

  • 20. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
    Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J, Huang S.
    Oncotarget; 2015 Mar 30; 6(9):7136-50. PubMed ID: 25762619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.